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Abstract Large epidemiologic studies of gout can improve
insight into the etiology, pathology, impact, and manage-
ment of the disease. Identification of monosodium urate
monohydrate crystals is considered the gold standard for
diagnosis, but its application is often not possible in large
studies. Therefore, under such circumstances, several proxy
approaches are used to classify patients as having gout,
including ICD coding in several types of databases or
questionnaires that are usually based on the existing
classification criteria. However, agreement among these
methods is disappointing. Moreover, studies use the terms
acute, recurrent, and chronic gout in different ways and
without clear definitions. Better definitions of the different
manifestations and stages of gout may provide better
insight into the natural course and burden of disease and
can be the basis for valid approaches to correctly
classifying patients within large epidemiologic studies.
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Introduction
Epidemiology can be defined as the study of the occurrence
and distribution of disease and its determinants [1]. In a
broader approach, the areas of research in epidemiology
include disease definition, occurrence, causation, outcome,
management, and prevention. The occurrence of a disease
may be studied in relation to factors that can identify or
predict the disease (diagnostic factors) or are thought to
influence its occurrence (eg, prognostic or etiologic factors).
Furthermore,the associationbetween a particularintervention
and a change in the occurrence of the disease is of importance
[2].
In a recent review on rheumatic diseases, Gabriel and
Michaud [3￿] acknowledged that until recently, very few
studies had been conducted on the epidemiology of gout.
Notwithstanding the rising incidence [4, 5], the burden of
disease associated with gout and the frequency of gout as a
comorbidity in patients with multiple morbidities highlight
the importance of gaining a better understanding of the
etiology, pathology, and management of gout through
epidemiologic studies.
This article focuses on the challenges of epidemiologic
studies that aim to estimate the occurrence of gout in terms
of prevalence or incidence. Such studies require large
sample sizes, especially in heterogeneous populations.
However, it is not only sample size that needs consideration
when conducting epidemiologic studies on the occurrence
of gout. This article considers some other deliberations.
First, the definitions used in studies of gout are
discussed, as well as the differences between diagnostic
and classification criteria. Next, the criteria regularly
used in epidemiologic studies are reviewed and critically
appraised. Finally, several additional challenges encoun-
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Definition of Disease
The gold standard to diagnose gout is to demonstrate
the presence of monosodium urate monohydrate (MSU)
crystals in synovial fluid at the time the patient
experiences a gout attack [6]. However, this is easier
said than done in clinical practice, as gout patients are
often seen by general practitioners [7] or specialists other
than rheumatologists, who rarely perform a synovial fluid
analysis to demonstrate urate crystals [8]. Reasons for
nonperformance include lack of expertise, limited access
to polarizing microscopes, lack of time, or the concern of
getting a “dry tap” [9]. If a joint aspiration is performed,
several difficulties remain, as both false-positive and
false-negative results may occur [10]. In some cases,
cholesterol crystals may appear as needle-shaped birefrin-
gent crystals [11, 12]. Furthermore, it is debatable whether
one can diagnose a patient as having gout when only one
or two MSU crystals are seen, or whether one should
perform a second joint aspiration if no crystals are
detected the first time. On the other hand, Lumbreras et
al. [13] showed that when observers are trained in crystal
detection and identification, their results are usually
consistent.
Although synovial fluid examination remains best
practice in clinical medicine, in the context of epidemiologic
studies, this may not be feasible, especially in view of the
intermittent nature of gout and the sample sizes that are
needed in population studies.
In studies, the terms gout flare, chronic gout, and acute
gout are regularly used. However, comparing their
definitions, if they are provided at all, these terms seem to
be used inconsistently by different authors. To facilitate the
comparability of study results, clear definitions of the
various manifestations and stages of gout therefore are
needed.
Taylor et al. [14￿￿] proposed key components of a
standard definition of gout flares using the Delphi method-
ology. The final list of elements includes a swollen, tender,
and warm joint; patient self-report of pain and global
assessment; time to maximum pain level; time to complete
resolution of pain; functional status; and an acute-phase
marker. This definition specifically aims to be used in
clinical trials.
Another frequently used term is chronic gout. Inter-
estingly, although a core set of outcome domains to be
used in clinical trials was proposed by OMERACT
(Outcome Measures in Rheumatology Clinical Trials)
[15], the group did actually not provide a clear definition
of chronic gout but agreed on serum urate, gout flare
recurrence, tophus regression, joint damage imaging,
health-related quality of life, musculoskeletal function,
patient global assessment, participation, safety, and toler-
ability as core outcome domains to be assessed in trials on
gout.
F o rC h o ie ta l .[ 16], acute gout is typically intermittent,
whereas chronic tophaceous gout develops after years of
acute intermittent gout. However, they point out that tophi
can also be part of the initial presentation. This is in line
with the American College of Rheumatology (ACR)
criteria for acute gout, which incorporate the item “more
than one attack of acute arthritis” as well as suspicion of a
tophus.
Others state that after a certain undefined number of
attacks, a patient has reached a stage called recurrent gout.
Then the attacks come more frequently and last longer. If a
patient cannot recover from the flares, it becomes chronic
gout. In that case, there is an almost permanent state of
inflammation and pain. Some authors have a more inclusive
definition of chronic gout, incorporating all patients who
have had more than one attack of acute gout. Acute gout, in
that case, is synonymous with gout flare. The underlying
reasoning is that once a patient has had a flare, a persistent
metabolic disorder exists.
In addition to these deliberations, one might think of
gout as a continuum of increasing severity. Currently, a
clear definition of severity is lacking. A first step would
be to define the domains that are of importance when
deciding on the severity of gout. Of interest is a recent
study that explored which variables are associated with
patients’ as opposed to physicians’ assessment of gout
severity [17]. It was found that physicians base their
judgment of severity on the presence of tophi, frequency
of gout attacks during the past year, recent serum uric acid
levels, and rheumatologist utilization, whereas patients’
judgment of severity is associated with concerns regarding
gout during an attack and the time since the last gout
attack. It will be a challenge to try to measure each of
these domains and to define thresholds to distinguish
levels of severity based on the selected domains. This may
also include addressing issues such as total load of uric
acid and total load of tophi.
In summary, the question remains whether intermittent
or recurrent gout must be distinguished from chronic gout
and, if so, at which point acute or recurrent gout develops
into chronic gout. Can we speak of chronic gout after a
number of attacks or after a specific period of recurrent
attacks, or only when a patient has bone destruction and
chronic synovitis, even during remission of acute flares?
Should we make a distinction between chronic gout and
tophaceous gout, and should we distinguish different levels
of severity of gout?
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the lack of insight into the natural course of gout among all
patients complicates this issue. Some patients may not
recall attacks of symptomatic gout, and patients with
tophaceous gout may no longer experience acute attacks.
This underlines the problem of assessing the true
prevalence of gout. Moreover, the gold standard for
diagnosing gout does not discriminate between different
“stages” of gout. Clearly, a need exists for consensus on
definitions that help distinguish the different manifesta-
tions of the disease.
Diagnostic Criteria Versus Classification Criteria
The title of this article may seem contradictory because in
epidemiologic studies, no diagnostic criteria other than
classification criteria are applied. Classification criteria aim
to define homogeneous groups of patients with a particular
disease. These criteria can be used to select patients for
clinical (interventional) studies, to compare the results of
clinical trials, or to assess the occurrence of a disease in
epidemiologic studies [18]. In contrast to diagnostic
criteria, classification criteria do not have the purpose of
early detection of a disease in an individual patient [19].
Instead, classification criteria are used to detect established
cases.
As for diagnostic tests, calculating the sensitivity and
specificity assesses the usefulness of criteria. Sensitivity
is the percentage of individuals with a certain disease
correctly classified as “ill” (true positives). The percent-
age of individuals without the disease correctly labeled
as “not ill” is the specificity (100% - percentage of false
positives). If the sensitivity and specificity of criteria are
both 100%, diagnostic and classification criteria are the
same [19]. Note that diagnostic criteria would require
sufficient sensitivity in early stages of the disease to
enable early diagnosis. However, the nature of medicine
makes it unlikely that there will ever be tests that offer
100% sensitivity and specificity. Therefore, misclassifica-
tion poses a challenge, and the type of misclassification
that is least desirable will depend on the setting in which
the test is applied.
In health care, physicians must identify which disease
a patient has rather than whether a disease exists at all
[19]. They do not want to misdiagnose a patient and may
prefer high sensitivity against acceptable specificity. In
contrast, in epidemiologic studies in large populations, to
study homogeneous groups that are likely to have the
diagnosis of interest but do not include many false
positives, the researchers must balance specificity and
sensitivity and will often sacrifice part of sensitivity
against better specificity.
Of course, any misclassification, which is common in
classification criteria, is undesirable [19]. An approach to
minimize misclassification is the use of cut-off points. In
deciding on a cut-off point, one has to choose between a
sensitive approach—involving false positives—and a more
specific approach that results in a more homogeneous group
and more false negatives [19].
Classification criteria often are developed by comparing
groups with the disease of interest with control patients
having other (usually related or resembling) diseases that
should be taken into account in the differential diagnosis.
However, one must keep in mind that if these criteria are
applied in population studies, the positive predictive value
(PPV) may decrease, especially when the prevalence of the
disease of interest is low. The PPV is defined as the number
of individuals with a true positive test result divided by all
individuals with a positive test result (true positives + false
positives). In other words, it indicates the probability that in
case of a positive test, the patient truly has the specified
disease. The value of PPV depends on the prevalence of the
disease of interest in the particular setting and will decrease
when the prevalence goes down, due to the increasing
number of false positives.
Thus, when applying the criteria for gout, a disease with
a relatively low prevalence at the general population level,
it is important to keep in mind that the estimated prevalence
may be overestimated due to the unintended inclusion of
false positives.
Overview of Criteria
In this section, criteria to assess the prevalence of gout in
epidemiologic studies are described. For this purpose,
PubMed was searched using the search terms “gout,”
“incidence,”“ prevalence,” and “epidemiology.” Only
original articles describing the prevalence and incidence
of gout were considered. The EULAR (European League
Against Rheumatism) criteria, which are purely diagnos-
tic criteria and intended for use in individual patients
with arthritis and not for use in groups, are excluded.
In 1963, the Rome criteria for gout were proposed
during a symposium on population studies (Table 1). These
and the 1966 New York criteria, which are a modification
of the Rome criteria, are based on expert opinion and aimed
for application in epidemiologic studies (Table 1)[ 18].
They rely heavily on the presence of tophi and the
observation of MSU crystals in synovial fluid, which
causes some feasibility issues. This is probably why both
criteria sets are rarely used in large epidemiologic studies.
The Rome criteria have only been used in two population
studies assessing the prevalence or incidence of gout, once
as interview [20] and once as questionnaire [21], and both
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New York criteria have been used in several population
studies in the same way as the Rome criteria [21–24].
It should be noted that for use in population surveys, the
items that make up criteria likely need to be rephrased into
questions that are answerable by patients using question-
naires or participating in interviews.
Currently, the most frequently used methods to
identify people with gout in epidemiologic studies are
theACRcriteria—formerAmericanRheumatismAssociation
criteria—using an interview approach and the ICD-9.
The ACR criteria for gout have been developed to
achieve a uniform system for reporting and comparing data
from studies (Table 1)[ 6]. They have been developed by
comparing different sets of criteria among gout patients and
patients with classic rheumatoid arthritis of 2 years’ or less
duration, definite or classic rheumatoid arthritis of more
than 2 years’ duration, pseudogout, or acute septic arthritis.
All have been diagnosed by rheumatologists. As such, the
ACR criteria for gout focus on acute arthritis of primary
gout and can be used in single patients as well as in
population surveys [6].
In large studies on the occurrence of gout, the ACR
criteria are often applied by interviewing patients with or
without a standardized questionnaire, or by chart review of
medical records. Although the ACR criteria were developed
for the diagnosis of acute gout, they also have been used to
identify so-called chronic gout, when patients fulfill the
item tophi or radiographic abnormalities. Compared with
the Rome and New York criteria, the ACR criteria rely less
on the presence of tophi or identification of MSU crystals
and even allow classification based on clinical criteria
alone. Malik et al. [25] applied the ACR, New York, and
Rome criteria in patients who had joint effusions in the
setting of a rheumatology clinic. They asked patients
whether they had experienced any of the clinical features
of these three sets of criteria. The researchers found the
highest specificity (89%) and PPV (77%) for the Rome
criteria. However, the criteria were slightly less sensitive
(67%). The New York criteria showed sensitivity and PPV
of 70% and specificity of 83%. The ACR criteria (6 of 12
clinical items) had 70% sensitivity and 79% specificity and
a PPV of only 66%. Clearly, one should not extrapolate
such findings to an epidemiologic population study,
because the PPV varies with the pretest probability, which,
as mentioned previously, is highly dependent on the
prevalence of the disease. Janssens et al. [26] compared
the ACR criteria with synovial fluid analysis as a gold
standard in monoarthritic patients presenting to primary
care. Only patients who were suspected of having gout
were included in the study. They found a PPV and a
sensitivity of 80%, while specificity was 64%. According to
Janssens et al. [26], these findings stress the importance of
interpreting with caution the results of gout studies that
made use of the ACR criteria.
A common method used to estimate the prevalence of
gout is the use of large medical databases that have
registered diseases by ICD-9 coding. Examples of data-
Table 1 Classification criteria for gout
Rome criteria New York criteria American College of Rheumatology criteria
Two of the following 4 criteria must
be present to make a diagnosis of
gout:
Urate crystals in synovial fluid or
tissue or presence of at least 2 of
the following:
Preliminary criteria for the classification of the acute arthritis of
primary gout
1. Serum uric acid level ≥7.0 mg/dL in
men, or ≥6.0 mg/dL in women
1. History or observation of at least
2 attacks of painful limb swelling
with remission within 1–2 week
A. Monosodium urate monohydrate crystals in synovial fluid, or
2. Tophus 2. History or observation of
podagra
B. Tophus, or
3. Urate crystals in synovial fluid or
tissues
3. Presence of tophus C. Presence of at least 6 of the following:
4. History of attacks of painful joint
swelling of abrupt onset with
remission within 1–2 week
4. History or observation of a good
response to colchicines (major
reduction in objective signs of
inflammation within 24 h of
onset of therapy)
1. More than 1 attack of acute arthritis
2. Maximal inflammation developed within 24 h
3. Monoarthritis attack
4. Redness observed over joints
5. First metatarsophalangeal joint painful or swollen
6. Unilateral first metatarsophalangeal joint attack
7. Unilateral tarsal joint attack
8. Tophus (suspected)
9. Hyperuricemia
10. Asymmetric swelling within a joint on radiograph
11. Joint fluid culture negative for organisms during attacks
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systems, administrative claims, and insurance programs.
Advantages of such databases are the large numbers
available at low expenses and the efficient time investment.
A disadvantage is that it remains unclear how the diagnosis
was made by the variety of health professionals and how to
generalize the results because the denominator is often
unclear. Malik et al. [27] evaluated the possibility of
documenting the accuracy of the ICD-9 code for gout in
three databases (National Patient Care Database, Pharmacy
Benefits Management Database, and the Clinical and
Administrative Database) by identifying patients with two
ICD-9–coded encounters for gout during a 6-year time
period. They found that identifying the items of the ACR,
New York, or Rome criteria in medical records could not
validate the majority of gout diagnoses recorded by ICD-9.
This discrepancy may be caused by inadequate docu-
mentation in medical records, inaccurate diagnostic
coding, or the inappropriateness of current criteria.
According to Malik et al. [27], it is the poor documen-
tation in medical records rather than inaccurate diagnostic
coding. Harrold et al. [28] analyzed a random sample of
medical records of patients with two or more coded
diagnoses of gout from four managed care plans. The
PPV of two or more ambulatory claims (during a time
period of 5 years) for a diagnosis of gout was assessed
using the investigators’ rating of the presence or absence
of definite or probable gout as the gold standard. The PPV
turned out to be 61%. Substantial improvement in the PPV
was not achieved by increasing the number of visits to
three or four. Explanations for the disappointing PPV
include the ambiguity of a diagnosis of gout compared
with, for example, a more firm diagnosis of myocardial
infarction; the assignation of an ICD code before the
diagnosis was firmly established; the underutilization of
synovial fluid analysis; and inadequate documentation in
medical records [28].
Self-reported disease, sometimes completed with infor-
mation from other medical sources, is often applied in
epidemiologic studies of gout. However, it is difficult to
distinguish between questionnaires that inquire about
physician-diagnosed gout and questionnaires that inquire
about manifestations typical of gout based on the existing
criteria described above. Furthermore, such questionnaires
vary in the time frame in which gout occurred, which can
be one or more attacks at some point in the past or several
attacks in a specific (limited) period of time preceding the
survey. Miller et al. [29] analyzed the agreement between
self-reported diseases and ICD-9 coding. These authors
indicated that self-report is fairly reliable. However, only
50% of self-reported cases of arthritis could be confirmed
by ICD coding [29]. Reasons for this lack of agreement
may be that responders have interpreted a question
incorrectly or have recalled a diagnosis that was not
actually established or was recalled inaccurately. However,
if patients are not receiving medication or other treatment,
the diagnostic code for a certain condition may not be
written down in the record [29]. Miller et al. [29] pointed
out that acute events that occurred in the past and
conditions that are episodic in nature are not always
captured if the reviewing period is too short.
It should be noted that questionnaires are often
operationalized through an interview approach. Although
self-completed questionnaires may cover a large popula-
tion in a relatively short time period at low cost, the
downside is a possible low response rate. Using an
interview approach, it is possible to ensure that all
questions are answered in the correct manner. However,
this method is more prone to interviewer bias and
interviewer variability [1]. Bergmann et al. [30] reported
that the agreement between a face-to-face interview and a
self-administered questionnaire was moderate (κ, 0.61).
Less serious, less defined, or less persistent diseases such
as gout may be perceived by patients as not being
important enough to report in questionnaires [30].
Of interest might be the diagnostic rule for acute gouty
arthritis recently developed by Janssens et al. [31￿]. It is
intended to be applied in primary care and obviate joint
aspiration. Based on validated clinical variables using
synovial fluid analysis as a reference test, a multivariate
logistic regression model was developed. Hereafter, they
developed two models based on external knowledge and
availability of the tool in clinical practice. Their final model
includes seven variables: male sex, previous patient-
reported arthritis attack, onset within 1 day, joint redness,
first metatarsophalangeal joint involvement, hypertension,
or one or more cardiovascular diseases and serum uric acid
level exceeding 5.88 mg/dL (0.35 mmol/L). Although
developed for use in primary care, the diagnostic rule
may be useful in a research setting. However, it is not
known how well this model performs in a population
study (work in progress).
Interpretation of Results
In addition to the above considerations that are critical in
the appraisal of data on the occurrence of disease, several
other issues merit consideration when appraising the results
of such studies [32]. First is the question of which type of
epidemiologic measure of occurrence was applied. The
nature of disease will influence the relevant study design
and measure of occurrence that is most informative [1]. As
acute flares of arthritis mainly characterize gout, the point
prevalence estimate (Table 2) is not likely of primary
interest. In fact, in a cross-sectional population study, the
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exactly the time of the survey is low. In this case, the period
prevalence, which represents individuals who experienced
one or more episodes over a specified period preceding the
survey (Table 2), will be more informative. Only if “chronic
gout” would be described in terms of persistent joint
inflammation, presence of irreversible joint damage, or
presence of tophi would the point prevalence be interesting.
Another important concept in epidemiologic studies is the
incidenceorincidencerate,whichreferstothe numberofnew
cases of gout in a population (Table 2). Cumulative incidence
refers to new cases of gout per year divided by all members
of a cohort (ie, a closed population) who are at risk (ie, who
never experienced any signs of gout before the observation
period). In contrast, incidence density refers to new cases of
gout per person-year in a dynamic population, such as the
inhabitants of a region or municipality (Table 2).
It is also important to carefully consider the population
that has been studied [2]. As for any epidemiologic study,
the sample should be a correct representation of the
population of interest; this requires insight into the
sampling frame and participation rate. The participation
rate should be at least as high as 80%; however, a rate
between 60% and 80% with a description of the non-
responders is often considered acceptable. Furthermore, to
guarantee the representativeness of the samples in studies
on gout, it is important to take into account sources of
(selection) bias, such as the age, sex, and race of the study
population. Determining the prevalence in a preponderant
older male population will overestimate the occurrence of
gout in the general population. One also should be aware of
confounding factors such as alcohol consumption, body
mass index, and comorbidities. Obesity, diabetes, and
hypertension are common among patients with gout [33],
and the prevalence of the metabolic syndrome is higher
than in patients without gout [34, 35].
Conclusions
Although the pathophysiology of gout is relatively well-
understood, it is surprisingly difficult to define good
classification criteria for use in large population studies to
validly assess the prevalence and burden of gout. This is
partially due to the nature of the disease, which is typically
intermittent, which limits the ability to use MSU crystals as
the gold standard in large epidemiologic studies.
Also challenging is the absence of clear insight into the
natural course of the disease, which would require better
definitions of the manifestations and stages of gout.
Although there is general agreement that gout is likely the
result of a longstanding metabolic disorder that eventually
leads to clinically manifest gout, it is less clear how many
patients will progress to tophaceous gout and develop joint
damage.
In view of the aforementioned considerations, literature
data on the prevalence of gout are surprisingly consistent.
In developed countries, estimates vary between 1% and 2%
[36]. Nevertheless, as discussed previously, different levels
of misclassification must have occurred in these studies.
This will hamper interpretation of the results, especially in
light of risk factors and comorbidities associated with gout.
More precise estimates of the prevalence and burden of
gout require addressing the validity of classification criteria
and proper definitions of the various manifestations and
stages of severity of gout.
Table 2 Conceptual framework of incidence and prevalence in studies of gout
Incidence
Cumulative incidence To be assessed in a cohort: number of new cases of gout per year divided by the population at risk (ie, all cohort
members who at the initiation of the cohort or at the start of the year of incidence assessment had never
experienced any manifestation of gout)
Incidence density To be assessed in a dynamic population (eg, the inhabitants of New York City): number of new cases of gout per
year divided by the number of person-years of individuals at risk. One person-year is defined as 1 person who
is at risk for a 1-year period (eg, if an individual gets gout after 3 months, he or she is counted as 0.25-person
years in the denominator). Thus, the denominator of incidence density (ie, the number of person-years in a
dynamic population) is not only determined by the changing size of the total population (eg, accounting for
individuals entering and leaving the municipality of New York, as well as newborns and deaths) but also by the
number of hitherto-healthy individuals who for the first time get gout during the observation period and are
therefore (from that moment onward) no longer “at risk” of newly getting gout
Prevalence
Point prevalence Number of cases of gout in the study population at a given point in time divided by the total study population.
This comprises the (usually few) individuals who suffer from an acute attack of gout at the concerned point in
time together with all those who then have chronic (tophaceous or nontophaceous) gout
Period prevalence Number of cases of gout in the study population during a specified period of time divided by the mean size of the
total study population over the concerned period. This comprises all individuals who have experienced an acute
attack of gout during that period together with all cases of chronic (tophaceous or nontophaceous) gout
172 Curr Rheumatol Rep (2011) 13:167–174McAdams et al. [37] reported recently that self-report of
physician-diagnosed gout has good reliability and sensitiv-
ity and that this method may seem appropriate for
epidemiologic studies.
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